{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:48:30Z","timestamp":1773294510356,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T00:00:00Z","timestamp":1500076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shire Development LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40263-017-0455-7","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T08:10:58Z","timestamp":1500106258000},"page":"685-697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit\/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study"],"prefix":"10.1007","volume":"31","author":[{"given":"Richard H.","family":"Weisler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margo","family":"Jaffee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,15]]},"reference":[{"issue":"18","key":"455_CR1","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.5453","volume":"315","author":"E Chan","year":"2016","unstructured":"Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit\/hyperactivity disorder in adolescents: a systematic review. JAMA. 2016;315(18):1997\u20132008.","journal-title":"JAMA."},{"issue":"3","key":"455_CR2","first-page":"192","volume":"21","author":"L Briars","year":"2016","unstructured":"Briars L, Todd T. A review of pharmacological management of attention-deficit\/hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21(3):192\u2013206.","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"6","key":"455_CR3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2215-0366(16)30032-3","volume":"3","author":"P Asherson","year":"2016","unstructured":"Asherson P, Buitelaar J, Faraone SV, et al. Adult attention-deficit hyperactivity disorder: key conceptual issues. Lancet Psychiatry. 2016;3(6):568\u201378.","journal-title":"Lancet Psychiatry."},{"issue":"7","key":"455_CR4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/mp.2016.74","volume":"21","author":"C Bonvicini","year":"2016","unstructured":"Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016;21(7):872\u201384.","journal-title":"Mol Psychiatry."},{"issue":"3","key":"455_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3810\/pgm.2008.09.1905","volume":"120","author":"AL Rostain","year":"2008","unstructured":"Rostain AL. Attention-deficit\/hyperactivity disorder in adults: evidence-based recommendations for management. Postgrad Med. 2008;120(3):27\u201338.","journal-title":"Postgrad Med."},{"key":"455_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-244X-10-67","volume":"10","author":"SJ Kooij","year":"2010","unstructured":"Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67.","journal-title":"BMC Psychiatry."},{"issue":"7","key":"455_CR7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","volume":"46","author":"S Pliszka","year":"2007","unstructured":"Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894\u2013921.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"3","key":"455_CR8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1542\/9781581108736-adhd_diagnosis","volume":"24","author":"M Thomas","year":"2013","unstructured":"Thomas M, Rostain A, Prevatt F. ADHD diagnosis and treatment in college students and young adults. Adolesc Med State Art Rev. 2013;24(3):659\u201379.","journal-title":"Adolesc Med State Art Rev."},{"key":"455_CR9","doi-asserted-by":"publisher","unstructured":"Jain R, Katic A. Current and investigational medication delivery systems for treating attention-deficit\/hyperactivity disorder. Prim Care Companion CNS Disord. 2016;18(4). doi: 10.4088\/PCC.16r01979 .","DOI":"10.4088\/PCC.16r01979"},{"issue":"10","key":"455_CR10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1176\/appi.ajp.2016.15091207","volume":"173","author":"JJ McGough","year":"2016","unstructured":"McGough JJ. Treatment controversies in adult ADHD. Am J Psychiatry. 2016;173(10):960\u20136.","journal-title":"Am J Psychiatry."},{"key":"455_CR11","volume-title":"Adult ADHD","author":"L Adler","year":"2004","unstructured":"Adler L. Adult ADHD. Washington, DC: Institute on Adult Presentation of Childhood Disorders, American Academy of Child and Adolescent Psychiatry; 2004."},{"issue":"5","key":"455_CR12","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1185\/030079907X182095","volume":"23","author":"JC Ermer","year":"2007","unstructured":"Ermer JC, Shojaei A, Pennick M, et al. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Curr Med Res Opin. 2007;23(5):1067\u201375.","journal-title":"Curr Med Res Opin."},{"key":"455_CR13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.4088\/JCP.v69n0911","volume":"69","author":"TJ Spencer","year":"2008","unstructured":"Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69:1437\u201348.","journal-title":"J Clin Psychiatry."},{"key":"455_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1087054717696770","author":"LA Adler","year":"2017","unstructured":"Adler LA, Frick G, Yan B. A long-term, open-label, safety study of triple-bead mixed amphetamine salts (SHP465) in adults with ADHD. J Atten Disord. 2017. doi: 10.1177\/1087054717696770 (Epub ahead of print).","journal-title":"J Atten Disord."},{"key":"455_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/1087054717696771","author":"G Frick","year":"2017","unstructured":"Frick G, Yan B, Adler LA. Triple-bead mixed amphetamine salts (SHP465) in adults with attention-deficit\/hyperactivity disorder: results of a phase 3, double-blind, randomized, forced-dose trial. J Atten Disord. 2017. doi: 10.1177\/1087054717696771 (Epub ahead of print).","journal-title":"J Atten Disord."},{"key":"455_CR16","volume-title":"ADHD Rating Scale-IV: checklists, norms, and clinical interpretation","author":"GJ DuPaul","year":"1998","unstructured":"DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. New York (NY): Guilford Press; 1998."},{"issue":"11","key":"455_CR17","first-page":"21","volume":"16","author":"DW Goodman","year":"2009","unstructured":"Goodman DW. ADHD in adults: update for clinicians on diagnosis and assessment. Prim Psychiatry. 2009;16(11):21\u201330.","journal-title":"Prim Psychiatry."},{"key":"455_CR18","volume-title":"Clinical Global Impressions","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical Global Impressions. Rockville: US Department of Health, Education, and Welfare; Public Health Service; Alcohol, Drug Abuse and Mental Health Administration; NIMH Psychopharmacology Research Branch; 1976."},{"issue":"12","key":"455_CR19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377.","journal-title":"Am J Psychiatry."},{"issue":"9","key":"455_CR20","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4088\/JCP.v69n0903","volume":"69","author":"LA Adler","year":"2008","unstructured":"Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364\u201373.","journal-title":"J Clin Psychiatry."},{"issue":"8","key":"455_CR21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1017\/S1092852900013687","volume":"11","author":"RH Weisler","year":"2006","unstructured":"Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625\u201339.","journal-title":"CNS Spectr."},{"key":"455_CR22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4088\/JCP.08m04902pur","volume":"71","author":"SV Faraone","year":"2010","unstructured":"Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit\/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754\u201363.","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"455_CR23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JCP.0b013e3181a390ce","volume":"29","author":"LA Adler","year":"2009","unstructured":"Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239\u201347.","journal-title":"J Clin Psychopharmacol."},{"issue":"12","key":"455_CR24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.biopsych.2006.07.032","volume":"61","author":"TJ Spencer","year":"2007","unstructured":"Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit\/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380\u20137.","journal-title":"Biol Psychiatry."},{"issue":"5","key":"455_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3810\/pgm.2014.09.2799","volume":"126","author":"AR Mao","year":"2014","unstructured":"Mao AR, Findling RL. Comorbidities in adult attention-deficit\/hyperactivity disorder: a practical guide to diagnosis in primary care. Postgrad Med. 2014;126(5):42\u201351.","journal-title":"Postgrad Med."},{"issue":"5 Suppl.","key":"455_CR26","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/1087054711435361","volume":"16","author":"JJ Kooij","year":"2012","unstructured":"Kooij JJ, Huss M, Asherson P, et al. Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord. 2012;16(5 Suppl.):3S\u201319S.","journal-title":"J Atten Disord."},{"issue":"1","key":"455_CR27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/appi.ajp.2015.15020266","volume":"173","author":"S Cortese","year":"2016","unstructured":"Cortese S, Moreira-Maia CR, St Fleur D, et al. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(1):34\u201343.","journal-title":"Am J Psychiatry."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0455-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0455-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0455-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T01:05:11Z","timestamp":1659229511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0455-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,15]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0455-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,15]]}}}